In the article “Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure” by Packer et al, which appeared in the December 1, 2009 of the journal (Circulation. 2009;120;2170–2176), a disclosure statement concerning Mark D. Carlson, MD was omitted.
The additional disclosure was added on page 2175 and should read, “Dr Carlson is the Cardiac Rhythm Management Division Chief Medical Officer with St. Jude Medical.”
The last sentence of the abstract also should have read, “Amiodarone had no effect on all-cause mortality or its cause-specific components, except an increase in non-cardiac mortality in class III patients.”
In addition, on page 2173, the second sentence under Impact of Type of HF on Mode of Death should read, “Of those, there were 221 deaths in those with NYHA class II HF of ischemic type, 141 deaths in those with NYHA class II HF and nonischemic type, 211 deaths in those with NYHA class III HF and ischemic type, and 93 deaths in those with NYHA class III of nonischemic type.”
The online version of the article has been corrected. The authors regret the error.